Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Imeglimin HCl 500 mg Tablets in Healthy Participants
NCT07691177Phase 1Completed
- Sponsor
- Humanis
- Start
- Feb 2026
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Peak Plasma Concentration at 72 hours and Area Under the Curve from time zero to time of last measurable concentration at 72 hours. Started Feb 2026; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07691177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691177.